Cost-effectiveness analysis of cardiac implantable electronic devices with reactive atrial-based antitachycardia pacing
EP Europace · 30.03.2023 · 25 (3) · 1087-1099
DOI: 10.1093/europace/euad003 ↗Kurz gefasst
Fachartikel in der Zeitschrift EP Europace, online erschienen am 24.01.2023. Verfasst von Takashi Noda und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center, 6-1 Kishibe-Shimmachi, Suita, Osaka 564-8565, Japan. Hauptthemen laut MEDLINE: Atrial Fibrillation, Cardiac Resynchronization Therapy, Heart Failure. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Medtronic Japan.
Abstract (Originalsprache)
Aims
Reactive atrial-based anti-tachycardia pacing (rATP) in pacemakers (PMs) and cardiac resynchronization therapy defibrillators (CRT-Ds) has been reported to prevent progression of atrial fibrillation, and this reduced progression is expected to decrease the risk of complications such as stroke and heart failure (HF). This study aimed to assess the cost-effectiveness of rATP in PMs and CRT-Ds in the Japanese public health insurance system. Methods and results We developed a Markov model comprising five states: bradycardia, post-stroke, mild HF, severe HF, and death. For devices with rATP and control devices without rATP, we compared the incremental cost-effectiveness ratio (ICER) from the payer's perspective. Costs were estimated from healthcare resource utilisation data in a Japanese claims database. We evaluated model uncertainty by analysing two scenarios for each device. The ICER was 763 729 JPY/QALY (5616 EUR/QALY) for PMs and 1,393 280 JPY/QALY (10 245 EUR/QALY) for CRT-Ds. In all scenarios, ICERs were below 5 million JPY/QALY (36 765 EUR/QALY), supporting robustness of the results.
Conclusion
According to a willingness to pay threshold of 5 million JPY/QALY, the devices with rATP were cost-effective compared with control devices without rATP, showing that the higher reimbursement price of the functional categories with rATP is justified from a healthcare economic perspective.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center, 6-1 Kishibe-Shimmachi, Suita, Osaka 564-8565, Japan.
- Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine and Tohoku University Hospital, 1-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi 980-8574, Japan.
- Healthcare Economics and Government Affairs, Medtronic Japan Co., Ltd., 1-2-70 Konan, Minato-ku, Tokyo 108-0075, Japan.
- Data Science Department, Medilead, Inc., 3-20-2 Nishi-Shinjuku, Shinjuku-ku, Tokyo 163-1424, Japan.
- Healthcare Consulting Inc., 1-8-19 Fujimi, Chiyoda-ku, Tokyo 102-0071, Japan.
- Government Affairs and Market Access, Medtronic Korea Ltd., #534, Teheran-ro, Gangnam-gu, Seoul 06181, Korea.
ORCID-Profile: Takashi Noda, Nobuhiko Ueda, Yuji Tanaka, Tatsuhiro Uenishi, Hiroko Yamaguchi, Ayako Shoji, Jae-Eun Myung, Kengo Kusano
Förderung
- Medtronic Japan
Zitieren
APA
Noda, T., Ueda, N., Tanaka, Y., Ishiguro, Y., Matsumoto, T., Uenishi, T., Yamaguchi, H., Shoji, A., Myung, J. E., & Kusano, K. (2023). Cost-effectiveness analysis of cardiac implantable electronic devices with reactive atrial-based antitachycardia pacing. EP Europace, 25(3), 1087-1099. https://doi.org/10.1093/europace/euad003
Vancouver
Noda T, Ueda N, Tanaka Y, Ishiguro Y, Matsumoto T, Uenishi T, et al. Cost-effectiveness analysis of cardiac implantable electronic devices with reactive atrial-based antitachycardia pacing. EP Europace. 2023;25(3):1087-1099. doi:10.1093/europace/euad003
BibTeX
@article{Noda2023,
author = {Noda, Takashi and Ueda, Nobuhiko and Tanaka, Yuji and Ishiguro, Yoko and Matsumoto, Tomoko and Uenishi, Tatsuhiro and Yamaguchi, Hiroko and Shoji, Ayako and Myung, Jae-Eun and Kusano, Kengo},
title = {Cost-effectiveness analysis of cardiac implantable electronic devices with reactive atrial-based antitachycardia pacing},
journal = {EP Europace},
year = {2023},
volume = {25},
number = {3},
pages = {1087--1099},
doi = {10.1093/europace/euad003}
}
EUVIMED